Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization
MWN-AI** Summary
Allarity Therapeutics, Inc. (NASDAQ: ALLR), a clinical-stage biopharmaceutical company focused on personalized cancer treatments, has successfully secured $20 million in non-convertible debt financing from Streeterville Capital. This financing, which consists of two promissory notes—one for approximately $10.93 million and another secured note for $10 million—aims to fund the advancement of stenoparib (2X-121), a dual inhibitor of PARP and the WNT pathway, towards FDA approval and commercialization.
The funding is anticipated to extend Allarity's cash runway through mid-2028, enabling the company to complete the Phase 2 clinical trial of stenoparib in patients with advanced ovarian cancer. The trial has previously shown promising results, with some patients experiencing durable benefits and prolonged survival times of over 30 months. CEO Thomas Jensen expressed confidence in the financing's impact, stating it will facilitate the completion of Phase 2 enrollment, preparations for an FDA meeting, and the advancement of their companion diagnostic strategy.
Stenoparib's unique mechanism—targeting both PARP and the tankyrase enzymes involved in the WNT signaling pathway—offers potential therapeutic benefits across various cancers, including ovarian, small cell lung, and colorectal cancers. Furthermore, Allarity has plans to leverage its proprietary Drug Response Predictor (DRP®) companion diagnostic platform to enhance treatment efficacy by identifying patients more likely to respond to therapy based on genetic profiles.
With the critical clinical data from the ongoing Phase 2 trial, Allarity seeks to demonstrate stenoparib's safety and effectiveness, positioning it favorably for future pivotal trials and regulatory engagement. The financing reflects Streeterville Capital's confidence in Allarity’s progress and the potential of stenoparib as a transformative therapy in oncology.
MWN-AI** Analysis
Allarity Therapeutics’ recent $20 million non-convertible debt financing, closed with Streeterville Capital, is a strategic move that could significantly enhance its prospects for the advancement of stenoparib (2X-121) toward FDA approval and commercialization. This financing is vital as it not only extends the company's cash runway into mid-2028 but also supports the completion of its Phase 2 clinical trial focused on ovarian cancer—a market with pressing unmet needs.
Investors should pay close attention to stenoparib's unique positioning: as a dual inhibitor targeting both PARP and the WNT pathway, it presents a novel approach that could differentiate it in a competitive landscape. Stenoparib has already shown promise, delivering significant overall survival benefits for heavily pre-treated ovarian cancer patients. Notably, some patients have remained on treatment for over 30 months, underscoring the drug's potential efficacy.
Furthermore, the company’s innovative Drug Response Predictor (DRP®) companion diagnostic adds a layer of sophistication to its development strategy. By identifying patients more likely to respond positively to the drug based on their genetic profile, Allarity not only enhances its clinical outcomes but also positions itself for strategic partnerships and collaborations down the line.
Despite these positive developments, investors should also remain cautious of inherent risks, including clinical trial uncertainties and regulatory challenges. Allarity's reliance on monumental milestones—like completing Phase 2 enrollment and preparing for pivotal trials—will be pivotal.
Considering these factors, current market positioning presents a unique opportunity for investors. With robust clinical data on the horizon and the financial backing to fuel growth, Allarity Therapeutics shows promise as a speculative investment within the biotech sector for those willing to navigate its associated risks.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
- Extends Company Cash Runway into Mid-2028
- Financing Expected to Fund Completion of Phase 2 Ovarian Cancer Trial
- Financing Supports Acceleration Toward Pivotal Trial and Commercialization
- Financing Structured as Non-Convertible Debt Financing
TARPON SPRINGS, Fla., March 6, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today announced that it has closed a $20 million non-convertible debt financing with Streeterville Capital.
The transaction is structured as a note purchase agreement pursuant to which the Company issued two non-convertible promissory notes: (i) a promissory note in the original principal amount of $10,930,000 and (ii) a secured promissory note in the original principal amount of $10,000,000, together providing approximately $20 million in net proceeds to the Company.
The financing is expected to extend the Company’s cash runway into the summer of 2028. The Company intends to use the proceeds primarily to support key initiatives designed to accelerate the advance of stenoparib toward pivotal development, FDA approval and commercialization.
Additional information regarding the transaction is included in the Company’s Form 8-K filed with the Securities and Exchange Commission on March 6, 2026.
“This financing demonstrates the confidence which Streeterville has in Allarity and the capital received positions us to complete Phase 2 enrollment, prepare for our FDA meeting, advance our companion diagnostic strategy, and prepare for pivotal development of stenoparib in advanced ovarian cancer,” said Thomas Jensen, Chief Executive Officer of Allarity Therapeutics. “The financing also supports broader strategic initiatives, including further advancement of our DRP companion diagnostic platform and potential exploratory development in additional WNT-driven tumor types. We view stenoparib as a novel, highly differentiated therapeutic candidate, and this non-convertible financing provides the resources necessary to propel its continued advancement, while reflecting confidence in the strength of our clinical progress and regulatory strategy.”
Stenoparib has demonstrated durable clinical benefit in heavily pre-treated ovarian cancer patients, including previously reported extended overall survival. Notably, certain patients have remained on therapy for more than 30 months, highlighting the long-term therapeutic potential of stenoparib in this population. The open-label Phase 2 trial will generate the critical clinical data to inform future regulatory engagement and pivotal trial development.
About Stenoparib/2X-121
Stenoparib is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and tankyrase 1/2. At present, tankyrases are attracting significant attention as emerging therapeutic targets for cancer, principally due to their role in regulating the WNT signaling pathway. Aberrant WNT/?-catenin signaling has been implicated in the development and progression of numerous cancers. By inhibiting PARP and blocking WNT pathway activation, stenoparib’s unique therapeutic action shows potential as a promising therapeutic for many cancer types, including ovarian cancer, Small Cell Lung Cancer and colorectal cancer. Allarity has secured exclusive global rights for the development and commercialization of stenoparib, which was originally developed by Eisai Co. Ltd. and was formerly known under the names E7449 and 2X-121. Allarity has two ongoing Phase 2 trial protocols for stenoparib in Ovarian Cancer patients. In the first, patients who had had 2+ lines of therapy were enrolled on stenoparib and given drug twice daily. This protocol has been closed to further enrollment but continues for the enrolled patients who are still receiving benefit from stenoparib administration. The updated data from this study were presented at this AACR special conference on advances in Ovarian Cancer. Note that, as these data are from an ongoing trial, analyses may change as the study fully matures. An amended protocol designed expressly to capitalize on the emerging clinical experience with stenoparib in platinum resistant patients began enrolling patients this summer. This amended protocol enrolls only platinum resistant or platinum-ineligible patients and is designed to accelerate the clinical development of stenoparib toward FDA approval.
About the Drug Response Predictor – DRP® Companion Diagnostic
Allarity uses its drug-specific DRP® to select those patients who, by the gene expression signature of their cancer, may have a high likelihood of benefiting from a specific drug. By screening patients before treatment, and only treating those patients with a sufficiently high, drug-specific DRP score, the therapeutic benefit rate may be enhanced. The DRP method builds on the comparison of sensitive vs. resistant human cancer cell lines, including transcriptomic information from cell lines, combined with clinical tumor biology filters and prior clinical trial outcomes. DRP is based on messenger RNA expression profiles from patient biopsies. The DRP® platform has shown an ability to provide a statistically significant prediction of the clinical outcome from drug treatment in cancer patients across dozens of clinical studies (both retrospective and prospective). The DRP platform, which may be useful in all cancer types and is patented for dozens of anti-cancer drugs, has been extensively published in the peer-reviewed literature.
About Allarity Therapeutics
Allarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage biopharmaceutical company dedicated to developing personalized cancer treatments. The Company is focused on development of stenoparib, a novel PARP/tankyrase inhibitor for advanced ovarian cancer patients, using its DRP® technology to develop a companion diagnostic that can be used to select those patients expected to derive the greatest clinical benefit from stenoparib. Allarity is headquartered in the U.S., with a research facility in Denmark, and is committed to addressing significant unmet medical needs in cancer treatment. For more information, visit www.allarity.com.
Follow Allarity on Social Media
LinkedIn: https://www.linkedin.com/company/allaritytx/
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide the Company’s current expectations or forecasts of future events. The words “anticipates,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predicts,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements regarding the continued clinical development of stenoparib (2X-121) in advanced ovarian cancer and small cell lung cancer; the completion of Phase 2 enrollment; anticipated timing of critical clinical data; preparation for and timing of End-of-Phase-2 FDA meeting; potential initiation of pivotal development; the development and potential prospective use of the Company’s DRP® companion diagnostic platform; and potential exploratory development of stenoparib in additional oncology indications, including other WNT-driven tumor types; the anticipated use of proceeds from the debt financing; and the filing of a Current Report on Form 8-K. Any forward-looking statements in this press release are based on management’s current expectations of future events and are subject to multiple risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks related to clinical development and regulatory review, including the possibility that future clinical data, may not support safety, efficacy, or durability claims; risks that Phase 2 enrollment may not be completed as planned; delays in patient enrollment or trial completion; risks associated with preparation for or outcome of End-of-Phase-2 FDA meeting; uncertainties regarding potential initiation or timing of pivotal development; reliance on third-party investigators, clinical sites, and manufacturing partners; the predictive accuracy, regulatory acceptance, and clinical utility of the DRP® platform; risks related to exploratory development in additional tumor types; and the Company’s ability to secure sufficient funding or strategic partnerships to support its operations and development plans; risks relating to the Company’s ability to deploy the proceeds as anticipated; satisfy its obligations under the debt instruments; complete and timely file the Form 8-K. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in our Form 10-K annual report filed with the Securities and Exchange Commission (the “SEC”) on March 31, 2025, and our Form 10-Q quarterly reports filed with the SEC on May 9, 2025, August 15, 2025 and November 14, 2025, available at the SEC’s website at www.sec.gov, and as well as discussions of potential risks, uncertainties and other important factors in the Company’s subsequent filings with the SEC. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law.
###
Company Contact:
investorrelations@allarity.com
Media Contact:
Thomas Pedersen
Carrotize PR & Communications
+45 6062 9390
tsp@carrotize.com
Attachment
FAQ**
How does the recent $20 million non-convertible debt financing enhance Allarity Therapeutics Inc. (NASDAQ: ALLR)’s position for completing the Phase 2 Ovarian Cancer trial and preparing for FDA approval?
What specific strategies will Allarity Therapeutics Inc. (NASDAQ: ALLR) implement utilizing the proceeds from the financing to accelerate the development of stenoparib in advanced ovarian cancer?
Following the extended cash runway into mid-2028, what key milestones does Allarity Therapeutics Inc. (NASDAQ: ALLR) anticipate achieving in the next two years to further its oncology pipeline?
How will the success of Allarity Therapeutics Inc. (NASDAQ: ALLR) in its Phase 2 trials impact the prospects for their DRP® companion diagnostic platform and its potential in other oncology indications?
**MWN-AI FAQ is based on asking OpenAI questions about Allarity Therapeutics Inc. (NASDAQ: ALLR).
NASDAQ: ALLR
ALLR Trading
-2.76% G/L:
$1.2301 Last:
114,013 Volume:
$1.28 Open:
